Implantica's RefluxStop™ makes strides in the UK

"We really look forward to commencing sales with reimbursement in the UK, which will accelerate once Covid-19 subsides," said Peter Forsell, CEO of Implantica. "At this stage we are focusing on the NHS hospitals (publicly funded healthcare). We intend to collect standard of care data in a registry for RefluxStop, which has been prepared and is ready to be launched including a web-based data collection system." "We really look forward to commencing sales with reimbursement in the UK, which will...

"We really look forward to commencing sales with reimbursement in the UK, which will accelerate once Covid-19 subsides," said Peter Forsell, CEO of Implantica. "At this stage we are focusing on the NHS hospitals (publicly funded healthcare). We intend to collect standard of care data in a registry for RefluxStop, which has been prepared and is ready to be launched including a web-based data collection system."

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
[email protected]

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, [email protected]

The information was sent for publication, through the agency of the contact person set out above, on February 16, 2021 at 08:00 a.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-s-refluxstop--makes-strides-in-the-uk,c3287492

The following files are available for download: